Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude

GenSight Biologics to Host KOL Breakfast on May 23, 2019 in New York

KOL Event to present Phase 3 REVERSE&RESCUE results of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON), New York City

GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the Annual Meeting of the American Academy of Neurology (AAN)

GenSight Biologics announces presentation of 72-week data from the REVERSE & RESCUE Phase III trials of GS010 at the Annual Meeting of ARVO

Sonoma Eye 2019, Sonoma, CA

GenSight Biologics announces presentation of 72-week data from the REVERSE Phase III trial of GS010 at the 45th annual meeting of NANOS

9th EURETINA Winter Meeting, Prague, Czech Republic

ARVO Annual Meeting, Vancouver, BC, Canada

BioEurope Spring, Vienna, Austria